TD Cowen analyst Marc Frahm lowered the firm’s price target on Incyte to $93 from $100 and keeps an Outperform rating on the shares. The analyst said Incyte missed on Opzelura sales of 57M due to some transient effects and some more structural but he continues to believe there is a meaningful derm business emerging for the post-Jakafi period.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on INCY: